Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study of Brineura in CLN2 Disease
NCT02485899Phase 2Completed
- Sponsor
- BioMarin Pharmaceutical
- Start
- Feb 2015
- Primary completion
- Dec 2020
- Modality
- Replacement Enzymes
- Countries
- 4
01
Overview
A Phase 2 trial of cerliponase alfa in neuronal ceroid lipofuscinosis type 2 (CLN2), sponsored by BioMarin Pharmaceutical. Started Feb 2015; status: completed.
02
Drugs
cerliponase alfa
03
Conditions
neuronal ceroid lipofuscinosis type 2 (CLN2)
Beyond the preview
Go deeper on NCT02485899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02485899.